[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"geographic-atrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:geographic-atrophy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,44,73,95,125,148,161,191,212,235,259,288,316,338,361,384,426,455,478,501,523,548,575,604],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053345","phase-1-study-to-assess-the-adverse-events-and-how-intravitreal-abbv-6628-moves-through-the-body-of-adult-participants-with-geographic-atrophy-secondary-to-age-related-macular-degeneration-100053345",false,"NCT07160179","Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration","Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of ABBV-6628 in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration","Inclusion Criteria:\n\nStage 1 and Stage 2\n\n-Diagnosed with Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in the study eye.\n\nStage 1\n\n* Foveal or non-foveal GA with total GA lesion area ≥ 0.5 DA (1.25 mm2) in the study eye, as assessed by the investigator at Screening and confirmed by the central reading center prior to Baseline\u002FDay 1\n* Absence of choroidal neovascularization (CNV) in the study eye as assessed by the investigator at Screening and confirmed by the central reading center prior to Baseline\u002FDay 1. In addition, investigators should confirm eligibility prior to treatment administration on Baseline\u002FDay 1.\n\nStage 2\n\n* Non-foveal GA with total lesion area of 1 to 7 DA (2.5 to 17.5 mm2); within 0.5 to 1.5 mm from fovea center in the study eye, as assessed by the investigator at Screening and confirmed by the central reading center prior to Baseline\u002FDay 1.\n* Absence of CNV in both eyes as assessed by the investigator at Screening and confirmed by the central reading center prior to Baseline\u002FDay 1. In addition, investigators should confirm eligibility prior to treatment administration on Baseline\u002FDay 1.\n\nExclusion Criteria:\n\nStage 1 and Stage 2\n\n* History of recurrent or currently active ocular or intraocular inflammation (e.g., uveitis, endophthalmitis) in at least one eye at Screening and Baseline\u002FDay 1.\n* Active periocular, ocular, or intraocular infection in at least one eye at Baseline\u002FDay 1.\n* History or clinical signs of diabetic retinopathy, diabetic macular edema (DME), or any retinal vascular disease other than AMD in at least one eye at Screening and Baseline\u002FDay 1.","ALL","50 Years",{"count":19,"type":20},66,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","Age-related macular degeneration (AMD) is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. Geographic Atrophy (GA) is an advanced form of dry AMD. The purpose of this study is to assess the adverse events and how intravitreal ABBV-6628 moves through the body of adult participants with secondary to age-related macular degeneration\n\nABBV-6628 is an investigational monoclonal antibody fragment being developed for the treatment of geographic atrophy (GA) secondary to (AMD) age-related macular degeneration. Participants in the Stage 1 part will be placed in 1 of 4 groups, called treatment arms. Participants in Stage 2 will be placed into 1 of 2 groups. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis GA secondary to age-related macular degeneration will be enrolled. Around 66 participants will be enrolled in the study at approximately 27 sites across the US.\n\nParticipants in Stage 1 will be given ABBV-6628 as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection) with dose escalation. Participants in Stage 2 will receive ABBV-6628 or SYFOVRE, an approved treatment for geographic atrophy, administered as per the FDA-approved label. The treatment duration is approximately 22 months and 3 months of follow-up.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[27,28],"Geographic Atrophy","Age-Related Macular Degeneration",[27,28,30],"ABBV-6628","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2025-08-13",{"date":39,"type":20},"2029-10",{"name":41,"class":42},"AbbVie","INDUSTRY",5,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100576014","a-study-to-learn-how-avacincaptad-pegol-izervay-is-used-in-clinical-practice-in-people-who-have-geographic-atrophy-100576014","NCT06779773","A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy","A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP\u002FIZERVAY™) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration","Inclusion Criteria:\n\n* Patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in 1 or both eyes\n* Patient with a decision to treat with intravitreal avacincaptad pegol (ACP) prior to enrollment\n* Patient willingness to complete the patient reported outcome (PRO).\n\nExclusion Criteria:\n\n* Patients who have any contraindication or are not eligible for treatment with ACP, including the following:\n\n  * Active ocular or peri-ocular infection in either eye\n  * Active, suspected intraocular inflammation in either eye\n  * Hypersensitive to ACP or to any ingredient in the formulation\n* Patients currently participating in an investigational program with interventions outside of routine clinical practice.\n* Patients who have received ACP in the eye being considered for enrollment. Note: Patients who have received or are receiving ACP in the fellow eye at baseline are eligible to be included in the study.\n* Patients who have received any intravitreal complement inhibitor other than ACP in either eye. Note: Patients who have received an intravitreal complement inhibitor other than ACP in either eye and have completed the 90-day washout period are eligible to be included in the study.",{"count":52,"type":20},500,"OBSERVATIONAL","This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision.\n\nAvacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy.\n\nThis study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor have decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas).\n\nPeople that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for around 5 years.",[27,56],"Macular Degeneration",[58,59,60,61,62],"Avacincaptad Pegol","IZERVAY™","Treatment patterns","Safety","Functional Outcomes","2026-07-01",{"date":65,"type":35},"2026-07-02",{"date":67,"type":35},"2025-01-22",{"date":69,"type":20},"2030-10-31",{"name":71,"class":42},"Astellas Pharma Global Development, Inc.",65,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100609488","phase-1-a-safety-and-efficacy-study-of-a-one-time-intravitreal-injection-of-sar446597-in-participants-with-geographic-atrophy-secondary-to-age-related-macular-degeneration-100609488","NCT07215234","A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration","A Phase 1\u002F2, Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration","Inclusion Criteria:\n\n* 60 years old or above\n* Participants with diagnosis of GA secondary to age-related macular degeneration (AMD)\n* Study eye with best corrected visual acuity (BCVA) ETDRS Snellen equivalent for dose escalation (Part I) between 20\u002F40 and 20\u002F320 and for expansion (Part II) equal or better than 20\u002F200\n* Study eye with GA lesion measuring between 2.5 and 17.5 mm2 for dose escalation (Part I) and between 2.5 and 14.0 mm2 for expansion (Part II). For multifocal disease, study eye with at least one single lesion of more than 1.25mm2 for both Part I and Part II\n\nExclusion Criteria:\n\n* GA in the study eye caused by a disease different than AMD\n* Presence of neovascularization or a history of treatment with an anti vascular endothelial growth factor agent in the study eye\n* Any condition or treatment (ocular or systemic) or medical or surgical history in the study eye that may prevent visual acuity improvement or interfere with ocular safety or efficacy assessments\n* Current or history of systemic complement targeting treatment in the past 12 months\n* Use of ocular corticosteroids for 4 months (for ocular or periocular injections), 6 months (for intraocular implants) or 3 years (for long lasting intraocular implants) prior to screening in the study eye\n* History of macular laser photocoagulation treatment, photodynamic- or thermotherapy or photo biomodulation in the study eye\n* History of active ocular infection in the study eye in 6 months prior to screening\n* Presence of active ocular or periocular infections\n* Active uncontrolled glaucoma in the study eye\n* History of uveitis or scleritis in either eye\n* Previous gene therapy in either eye\n* Any significant poorly controlled illness that would preclude study compliance and follow up\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","60 Years",{"count":82,"type":20},104,[23,24],"This is a sequential Phase 1\u002F2, two-part, multicenter study on safety, tolerability, and efficacy of one-time intravitreal SAR446597 for the treatment of participants with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).\n\nThe core phase duration will be approximately 2 years for each participant. An Extended Follow-Up (EFU) phase of 3 years follows the core phase.\n\nThe treatment is a one-time intravitreal injection of SAR446597 (or sham as applicable in Part II).",[27],"2026-06-30",{"date":63,"type":35},{"date":89,"type":35},"2025-10-09",{"date":91,"type":20},"2032-07-22",{"name":93,"class":42},"Sanofi",18,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":124},"100388585","phase-1-autologous-transplantation-of-induced-pluripotent-stem-cell-derived-retinal-pigment-epithelium-for-geographic-atrophy-associated-with-age-related-macular-degeneration-100388585","NCT04339764","Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration","A Phase I\u002FIIa Trial for Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration","* INCLUSION CRITERIA:\n\nParticipant Eligibility Criteria:\n\nTo be eligible, the following inclusion criteria must be met, where applicable.\n\n* Participant must be 55 years of age or older.\n* Participant must have a diagnosis of dry AMD, defined as presence (or history, as documented in available color fundus photographs) of at least one medium or large druse (greater than or equal to 63 micrometer diameter) in the macula in at least one eye; AND presence of GA in at least one eye.\n* Participant must understand and sign the protocol s informed consent document.\n* Any participant of childbearing potential must have a negative pregnancy test at screening and must be willing to undergo pregnancy testing prior to RPE transplantation.\n* Any participant of childbearing potential and any participant able to father children who has a partner of childbearing potential must have (or have a partner who has) had a hysterectomy or vasectomy, be completely abstinent from intercourse, or must agree to practice an effective method of contraception through Month 12 in the study. Acceptable methods of contraception include:\n\n  * Hormonal contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal ring),\n  * Intrauterine device,\n  * Barrier methods (diaphragm, condom) with spermicide, or\n  * Surgical sterilization (tubal ligation).\n* Participant must be medically able to comply with the study treatment (including ability to safely receive anesthesia for surgery), study testing and procedures, and follow-up visits.\n\nStudy Eye\u002FFellow Eye Eligibility Criteria\n\nThe participant must have at least one eye meeting all inclusion criteria and none of the exclusion criteria listed below. The fellow eye must also meet the relevant eligibility criteria listed below.\n\nStudy Eye Inclusion Criteria:\n\n* The study eye must have one or more regions of geographic atrophy with total area of 1 disc area or more. A region of geographic atrophy is defined as an area of uniform hypofluorescence on fundus autofluorescence (FAF) imaging, with greatest linear dimension at least 500 micrometer, with a border within 500 micrometer of the foveal center, not compatible with pigmentary changes, drusen, RPE detachment, drusenoid RPE detachment, hemorrhage, or other lesion. (Note: If macular geographic atrophy is contiguous with peripapillary atrophy, complicating calculation of total area, only atrophy temporal to a vertical line placed a half disc diameter temporal to the temporal border of the disc will be included in the total area of geographic atrophy calculated for eligibility purposes.)\n* For participants in the first cohort, the study eye must have an ETDRS best-corrected visual acuity (BCVA) letter score of \\\u003C= 53 and \\>= CF (i.e., Snellen equivalent between 20\u002F100 and CF), and the fellow eye must have a letter score no more than five letters worse than the study eye using Electronic Visual Acuity (EVA) testing. If the study eye is CF vision, then the fellow eye must be both (1) CF or better vision and (2) subjectively as good or better than the study eye according to the subject s perception. (Note: Letter scores within five or fewer letters of each other are accordingly considered equal for eligibility determination, and other factors may be used to select the study eye if both are eligible by BCVA.\n* For participants in the second cohort, the study eye must have an ETDRS best-corrected visual acuity (BCVA) letter score of \\\u003C= 58 and \\>= CF (i.e., Snellen equivalent between 20\u002F80 and CF), and the fellow eye must have a letter score no more than five letters worse than the study eye using Electronic Visual Acuity (EVA) testing. If the study eye is CF vision, then the fellow eye must be both (1) CF or better vision and (2) subjectively as good or better than the study eye according to the subject s perception. (Note: Letter scores within five or fewer letters of each other are accordingly considered equal for eligibility determination, and other factors may be used to select the study eye if both are eligible by BCVA.\n* The compromise in visual acuity for the study eye must be judged predominantly secondary to dry AMD, in the judgment of the investigator.\n* The study eye must have clarity of ocular media and degree of pupil dilation sufficient to permit adequate fundus photography and safe vitrectomy surgery.\n* The study eye must be either pseudophakic or aphakic.\n\nEXCLUSION CRITERIA:\n\nA participant is not eligible if any of the following exclusion criteria are present:\n\n* Participant is actively receiving another study medication \u002F investigational product (IP).\n* Participant has any condition that significantly increases risk of systemic corticosteroids or systemic steroid-sparing immuno-modulatory agents, such as uncontrolled diabetes mellitus (defined as HbA1C \\> 7.5 at Baseline), chronic hepatitis or liver failure (defined, as elevated liver function tests (LFTs): alanine transaminase (ALT) or aspartate transaminase (AST) \\>= 2x upper limit of normal at Baseline), kidney disease with an eGFR \\\u003C25 mL\u002Fmin\u002F1.73 m2 for 3 months or more or by any other evidence of disease chronicity, or present infection with HIV, syphilis, tuberculosis, hepatitis B, or hepatitis C (past infection now resolved, where applicable, is not exclusionary; but persistent infection, even if latent, is exclusionary).\n* Participant has diagnosis of a malignancy expected to affect two-year survival.\n* Participant is pregnant, breast-feeding, or planning to become pregnant through the first 12 months of the study.\n* Participant has a family history of a retinal degeneration other than AMD suspected to play a role in the ocular phenotype of the participant in the judgment of the investigator, based on disease features and mode of inheritance, such as in a case of autosomal dominant retinal degeneration in a parent or child.\n* Participant is taking, or has taken within the previous year, medication with known potential toxicity to the retina, optic nerve, or lens (such as chloroquine, hydroxychloroquine, ethambutol).\n* Participant is taking any form of systemic anticoagulation which cannot be stopped for an indefinite period of time without significant risk. The determination of significant risk to the participant must be at the discretion of the study investigators and prescribing physician (or qualified alternative).\n* Participant is unable or unwilling to give informed consent that includes use of medical records and clinical samples for current and future research.\n\nStudy Eye Exclusion Criteria:\n\n* The study eye has macular, subretinal or choroidal neovascularization, as assessed by FA and OCT; or any history of such neovascularization (as assessed by past available records or images).\n* The study eye has serous or hemorrhagic pigment epithelial detachment, as assessed by FA and OCT, that is clinically significant in the judgment of the investigator.\n* The study eye has a history of photodynamic therapy (PDT) or macular thermal laser photocoagulation, or history of intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents or corticosteroids (excepting medications used peri-operatively at prior cataract surgery). The study eye has had intravitreal injections (anti-complement therapy) for treatment of dry AMD in the previous 12 weeks before enrollment. Any intravitreal injections with anti-complement therapy prior to 12 weeks are not exclusionary.\n* The study eye has an axial length \\> 25.0 mm.\n* The study eye has had surgery in the previous 12 weeks, or laser capsulotomy in the previous four weeks.\n* The study eye has chronic glaucoma; OR significant ocular hypertension, defined as documented intraocular pressure of \\>= 26 mmHg on at least two occasions in the absence of self-limited acute glaucoma; OR history of probable or definite steroid response manifesting as acute glaucoma or ocular hypertension, even if self-limited and no longer present; OR the fellow eye has evidence for present or past glaucoma or ocular hypertension judged to significantly impact the risk of glaucoma in the study eye (including history of probable or definite steroid response). (Note: History of self-limited acute glaucoma in a study or fellow eye, if not secondary to steroid response, and if now resolved and not expected to recur (e.g., history of elevated intraocular pressure from retained visco-elastic after cataract surgery), is not exclusionary. History of glaucoma or ocular hypertension in the fellow eye, if not felt to significantly impact risk of glaucoma in the study eye, is not exclusionary.)\n* The study eye has a condition materially increasing the risks of surgery or potentially affecting visual function over the next two years in the judgment of the investigator, such as chronic uveitis, diabetic retinopathy, keratitis, scleritis, optic neuropathy, untreated retinal detachment, macular edema from prior vein occlusion or other cause, proliferative vitreoretinopathy (PVR), vitreous hemorrhage, pathologic myopia, etc. A history of such conditions is not exclusionary, if judged to not materially increase risks of surgery or to potentially affect vision in the next two years in the opinion of the investigator.","55 Years","95 Years",{"count":105,"type":20},20,[23,24],"Background:\n\nAge-related macular degeneration is a common eye disease in people over 50. The \"dry\" form of the disease can worsen into geographic atrophy, causing blind spots. Researchers want to learn if replacing older eye cells with younger ones can help treat this disease.\n\nObjective:\n\nTo test the safety of putting cells inside the eye as a possible future treatment for dry age-related macular degeneration.\n\nEligibility:\n\nPeople ages 55 and older who have geographic atrophy with loss of vision. People who have had \"wet\" macular degeneration in study eye are NOT eligible.\n\nDesign:\n\nParticipants will be screened with:\n\n* Medical history\n* Physical exam\n* Blood and urine tests\n* Eye exam\n* Eye photos\n* Fluorescein angiography. An intravenous (IV) line is placed in an arm vein. A dye is injected. A camera takes pictures of the dye as it flows through the eyes' blood vessels.\n* Electroretinography. An electrode is taped to participants' forehead. They sit in the dark. After 30 minutes, numbing eye drops and contact lenses are placed in their eyes. They watch flashing lights.\n* Tuberculosis test\n* Chest X-ray\n* Electrocardiography. Sticky pads are placed on participants' chest to record the heart's electrical activity.\n\nParticipants will have at least 14 study visits over 5 and a half years. They will repeat screening tests.\n\nParticipants will have retinal pigment epithelium (RPE) transplantation surgery in one eye. For this, cells from participants' blood are turned into RPE cells. These cells are placed in their eye through a cut in their retina. They will get dilating eye drops, an IV line, and anesthesia that may make them sleep. A gas bubble will be put in their eye to help it heal. Participants will receive immunosuppressive medications to avoid transplant rejection.\n\nParticipants will be contacted yearly for up to 15 years.",[109,27],"Dry Age-Related Macular Degeneration",[111,112,113],"Retina","Cell Therapy","Vitrectomy","2026-06-23",{"date":116,"type":35},"2026-06-24",{"date":118,"type":35},"2020-09-23",{"date":120,"type":20},"2029-05-31",{"name":122,"class":123},"National Eye Institute (NEI)","NIH",2,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":147},"100487363","phase-2-a-study-to-optimize-subretinal-surgical-delivery-and-to-evaluate-safety-and-activity-of-opregen-in-participants-with-geographic-atrophy-secondary-to-age-related-macular-degeneration-galette-adaptive-optics-ao-retinal-imaging-substudy-in-association-with-study-gr44251-100487363","NCT05626114","A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251","A Phase IIa, Multicenter, Open-label, Single-Arm Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration","Inclusion Criteria:\n\n* Ability to undergo a vitreoretinal surgical procedure under monitored anesthesia care\n* Diagnosis of GA secondary to AMD\n* Best corrected visual acuity (BCVA) score ≥ 29 letters and ≤ 60 letters in the study eye as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS)\n* Pseudophakic (study eye)\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* History of cognitive impairment or dementia\n* Any type of systemic disease or its treatment, in the opinion of the investigator, including any medical conditions that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical status of the participant to a significant degree or put the participant at special risk\n\nOcular Exclusion Criteria for Study Eye:\n\n* Any current or history of ocular disease other than GA that may confound assessment of the macula\n* History of retinal detachment\n* History of vitrectomy, glaucoma-filtering surgery, or corneal transplant\n* Uncontrolled glaucoma or advanced glaucoma\n* Any cataract surgery or intraocular surgery within 3 months prior to subretinal surgical delivery of OpRegen\n* History of other ocular or intraocular conditions that contraindicate the use of an investigational drug or may affect interpretation of the study results or may render the participant at high risk for treatment complications\n* Any existing posterior segment device or implant\n\nSubstudy:\n\nInclusion Criteria:\n\n\\- Participants must meet all of the inclusion criteria described in the parent study GR44251 and have the ability to comply with the substudy protocol\n\nExclusion Criteria:\n\n* Participants who meet any exclusion criteria listed in the parent study GR44251\n* Past history of seizures, or epileptic seizures due to any cause except for a single febrile seizure in childhood",{"count":133,"type":20},60,[24],"This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated.\n\nThe substudy will evaluate the operational feasibility and scientific interpretability of incorporating AO retinal imaging using the EarlySight Cellularis® Discovery device. Participants who have fulfilled the eligibility requirements for the parent study and meet the substudy's eligibility criteria will have the option to participate in the substudy. The EarlySight Cellularis® Discovery device will be used only as an assessment tool and data obtained from this device will not be used to guide clinical care or influence clinical outcomes for participants.",[27],[138],"Geographic Atrophy Secondary to Age-related Macular Degeneration","2026-06-18",{"date":114,"type":35},{"date":142,"type":35},"2023-03-23",{"date":144,"type":20},"2031-03-01",{"name":146,"class":42},"Genentech, Inc.",17,{"id":149,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":25,"conditions":152,"keywords":153,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":158,"leadSponsor":159,"locationsCount":160},"100605258",{"count":19,"type":20},[23,24],[27,28],[27,28,30],"2026-06-11",{"date":156,"type":35},"2026-06-15",{"date":37,"type":35},{"date":39,"type":20},{"name":41,"class":42},4,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":168,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":21,"phases":171,"briefSummary":172,"conditions":173,"keywords":177,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":190},"100642827","phase-1-phase-1-study-of-c001-in-retinal-degeneration-100642827","NCT07594236","Phase 1 Study of C.001 in Retinal Degeneration","A Phase I Single-Center Open-label Study of C.001 in Patients With Significant Retinal Pigment Epithelium Mediated Maculopathy (RMM)","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of retinal disease associated with retinal pigment epithelium degeneration (e.g., geographic atrophy or Stargardt disease)\n* Visual acuity within protocol-defined limits\n* Stable ocular condition prior to enrollment\n* Medically suitable for ophthalmic surgery and anesthesia\n* Willingness to comply with study procedures and follow-up\n\nExclusion Criteria:\n\n* Active or prior choroidal neovascularization (CNV)\n* Recent myocardial infarction or significant uncontrolled cardiovascular disease\n* Uncontrolled glaucoma\n* Significant ocular inflammatory disease\n* Recent intraocular surgery within protocol-defined timeframe\n* Active systemic infection\n* Poorly controlled diabetes (e.g., HbA1c \\>8.5%)\n* Participation in another investigational study within 3 months prior to screening","18 Years",{"count":170,"type":20},15,[23],"This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium.\n\nParticipants will receive a single administration of C.001 delivered by subretinal injection. The study will evaluate three dose levels in a sequential manner.\n\nThe primary objective is to assess the safety of C.001 over a 3-month period following administration. Participants will be followed for up to 12 months to further evaluate safety and explore changes in visual function and retinal structure.",[27,174,175,176],"Stargardt Disease","RPE-mediated Maculopathy","Age Related Macular Degeneration",[178,179,180],"macular degeneration","macular distrophy","C.001","2026-06-10",{"date":183,"type":35},"2026-06-12",{"date":185,"type":35},"2026-04-07",{"date":187,"type":20},"2029-12-31",{"name":189,"class":42},"Cellio Therapeutics Inc",1,{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":21,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":82},"100564897","phase-2-a-long-term-extension-study-of-jnj-81201887-aavcagscd59-parent-studies-in-participants-with-geographic-atrophy-ga-secondary-to-age-related-macular-degeneration-amd-100564897","NCT06635148","A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","Long-term Extension Study for Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies","Inclusion Criteria:\n\n* Participants who were enrolled and received treatment with JNJ-81201887 or sham in a parent clinical study (81201887MDG2001, 81201887MDG1003)\n* Females (women of childbearing potential), male participants, and partners of male participants will not be required to use contraception in this LTE study\n* Must sign an informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. The ICF may be signed by an impartial witness and\u002For legally designated representative depending on national\u002Flocal regulations\n\nExclusion Criteria:\n\n* There are no exclusion criteria for this LTE study",{"count":199,"type":20},274,[24],"The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.",[27,56],"2026-06-04",{"date":205,"type":35},"2026-06-05",{"date":207,"type":35},"2024-09-19",{"date":209,"type":20},"2030-07-16",{"name":211,"class":42},"Janssen Research & Development, LLC",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":21,"phases":221,"briefSummary":222,"conditions":223,"keywords":224,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":133},"100639625","phase-2-a-study-in-adults-with-geographic-atrophy-100639625","NCT07606365","A Study in Adults With Geographic Atrophy","A Phase 2, Multicentre, Randomised, Double-masked, Placebo-controlled, Parallel-group, Dose-range Finding Study, to Assess the Efficacy and Safety of Oral STL303 in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration","Inclusion Criteria:\n\nThe study eye must meet all inclusion criteria. If both eyes meet the inclusion criteria, the eye with the better visual acuity at the Screening visit will be designated as the study eye. If both eyes have the same visual acuity, the right eye will be selected as the study eye.\n\n1. Participants ≥60 years of age at the time of Screening (signing the ICF).\n2. Diagnosis of non-exudative AMD in both eyes, with confirmed presence of phenotypic hallmarks of AMD such as hard and\u002For soft drusen.\n3. The GA lesion in the study eye must meet the following criteria as determined by the central Reading Centre's assessment at Screening:\n\n   1. Total GA area must be ≥2.5 and ≤10.16 mm2 (1 and 4 DA, respectively) as measured using SD-OCT.\n   2. If GA is multifocal, at least one focal lesion must be ≥1.25 mm2 (0.5 DA), with the overall aggregate area of GA, as specified above in 3a.\n   3. The entire GA lesion must be completely visualised on the 6 × 6 mm fovea-centred OCT scan and must be able to be imaged in its entirety and not contiguous with any areas of peripapillary atrophy.\n   4. The entire EZ loss border must be completely visualised on the 6 × 6 mm fovea centred OCT scan as determined by the central Reading Centre's assessment at Screening; in cases where the EZ loss border is close to the grid boundary, a grid centred on the atrophic area may be used at the Baseline visit (as advised by the Reading Centre).\n   5. All GA lesions must be at least 150 μm from foveal centre.\n4. Confirmed presence of any pattern of hyper-autofluorescence in the junctional zone of GA; absence of hyper-autofluorescence is exclusionary.\n5. BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) score of ≥55 letters (Snellen equivalent ≥20\u002F70) in the study eye at the Screening visit and Baseline visit.\n6. Low luminance visual acuity (LLVA) by ETDRS score of ≥10 letters in the study eye at the Screening visit and Baseline visit.\n7. Meets the following criteria related to microperimetry:\n\n   1. Able to detect fixation target.\n   2. Fixation losses must be ≤20%.\n   3. Participant is willing and able to undertake microperimetry assessment in the opinion of the Investigator.\n8. Able to take IMP or have an appropriate designee who can administer the IMP (i.e., a capable family member or caregiver).\n9. Able to provide written informed consent and willing to comply with all site visits, examinations, daily IMP administrations and dosing diary entries, and other conditions of the study protocol.\n10. Adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images as determined by the Investigator.\n11. The fellow eye may have any of the following: AMD without GA, AMD with GA, or foveal GA (ongoing treatment with complement inhibitor therapies in the fellow eye is allowed).\n12. Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection are required at least two weeks prior to the start of the treatment with STL303.\n13. If not received previously, vaccination against Haemophilus influenzae type b infection should be given, if available and according to local regulations.\n14. Body mass index (BMI) ≥18 kg\u002Fm2 to ≤40 kg\u002Fm2.\n15. Participants of childbearing potential (POCBP) must use an appropriate birth control if not confirmed postmenopausal; male participants with partners of childbearing potential must agree to use highly effective contraception methods during the study and for 1 month after the last dose of the IMP.\n16. Participants must agree to refrain from donating gametes during the duration of the study and for 1 month after the last dose of the IMP.\n\nExclusion Criteria:\n\n1. Atrophic retinal disease of causality other than AMD including myopia-related maculopathy and macular dystrophies such as pattern dystrophy and Stargardt disease in either eye.\n2. Evidence of ongoing exudative AMD, polypoidal choroidal vasculopathy, or macular neovascularisation in either eye by history, OCT, fluorescein angiography (FA) or optical coherence tomography angiography (OCTA) as determined by the Reading Centre (prior IVT treatment for CNV is permitted in the fellow eye so long as the last injection was more than two years previously).\n3. Previous treatment with any ocular photodynamic therapy or laser coagulation to the macula in the study eye.\n4. Presence of active\u002Fcurrent retinal vein occlusion in the study eye.\n5. Presence of vitreous haemorrhage in the study eye.\n6. History of retinal detachment in the study eye.\n7. Ocular conditions - either eye:\n\n   1. Presence of at least moderate non-proliferative diabetic retinopathy (or worse) in either eye (a history of diabetes mellitus without retinopathy and mild non-proliferative diabetic retinopathy is not a criterion for exclusion).\n   2. Presence of any other retinal pathology that, in the opinion of the Investigator, would confound the diagnosis or assessment of GA or would make follow-up not feasible.\n   3. History of herpetic infection in either eye.\n   4. Active uveitis and\u002For vitritis (grade trace or above) in either eye.\n   5. History of idiopathic or autoimmune-associated uveitis in either eye.\n   6. Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.\n   7. Spherical equivalent of the refractive error demonstrating \\>6 diopters of myopia or an axial length \\>26 mm in either eye.\n   8. Intraocular surgery (including lens replacement surgery) within 3 months prior to randomisation in either eye.\n   9. Yttrium Aluminium Garnet (YAG) laser in either eye within 1 month prior to randomisation.\n8. History of infection with Neisseria meningitidis, Streptococcus pneumoniae or Haemophilus influenzae type b despite vaccination.\n9. History or known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)-positivity (unless treated \\[for HBV and HCV only\\]) and achieved sustained viral response with negative polymerase chain reaction (PCR).\n10. Known ongoing immunodeficiency with or without treatment.\n11. Previous participation in a retinal gene therapy clinical study where the gene therapy was delivered to either eye.\n12. History of any prior IVT treatment for any indication other than AMD in either eye. Prior IVT treatment for CNV is permitted in the fellow eye so long as the last injection was more than two years previously.\n13. Any prior treatment for AMD in the study eye (for example, surgical, radiation, thermotherapeutic, or laser intervention), except oral supplements or minerals; prior treatment with Izervay or Syfovre is allowed in the study eye so long as 6 months have elapsed since the last treatment and so long as the participant did not experience any ocular inflammation or adverse events during the treatment with either Izervay or Syfovre. Ongoing treatment with Izervay or Syfovre is permitted in the fellow eye.\n14. Usage of systemic immunosuppressants or other immunomodulatory drugs within 90 days prior to the first administration or within 5 half-lives of the drug (whichever is longer), specifically including but not limited to cyclophosphamide, rituximab, infliximab, mycophenolate mofetil, cyclosporine, tacrolimus, sirolimus, systemic corticosteroids (inhaled or topical corticosteroids, or corticosteroids directly injected into the joints are allowed).\n15. Previous treatment with other systemic complement inhibitors within 30 days prior to the first dose, or within 5 half-lives of the drug, or within the potential period of residual effects from previous clinical studies, such as anti-sense oligonucleotide (ASO) or ribonucleic acid interference (RNAi), whichever is longer.\n16. Participants with any unstable or clinically significant medical condition that, in the opinion of the Investigator, could pose a risk of complications or interfere with participation during the course of the study.\n17. Participants with prolonged corrected QT interval (QTc) at Screening or at Baseline (QT interval corrected using Fridericia's formula \\[QTcF\\] \\>480 ms).\n18. Participants with clinically-relevant cardiac events within the last 2 years.\n19. Participants with significantly abnormal liver function at Screening or at Baseline: any parameter of ALT, AST, gamma glutamyl transferase (GGT) or alkaline phosphatase (ALP) \\>3 × upper limit of normal (ULN); serum bilirubin total \\>1.5 × ULN.\n20. Platelet count \\\u003C75000 cells\u002Fmm3.\n21. Haemoglobin value \\\u003C8 gm\u002FdL.\n22. History of end stage liver or kidney disease requiring dialysis or transplant.\n23. History of hypersensitivity to any of the study treatments or excipients or to drugs of similar chemical classes or clinically relevant sensitivity to fluorescein dye as assessed by the Investigator.\n24. History of alcohol or drug abuse within the last 5 years.\n25. Ongoing treatment with cytochrome P450 2C8 (CYP2C8) inhibitors, or inducers or strong P-glycoprotein inhibitors.\n26. Ongoing participation in any other clinical study.",{"count":220,"type":20},300,[24],"The purpose of this clinical research study is to look at how safe STL303 is and whether it works when given to people with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). Geographic atrophy secondary to AMD is a condition where cells in the back part of the eye slowly die, causing a blurry, or missing spot in the centre of vision.",[27],[28,27],"NOT_YET_RECRUITING","2026-05-24",{"date":228,"type":35},"2026-05-28",{"date":230,"type":20},"2026-06",{"date":232,"type":20},"2029-08",{"name":234,"class":42},"Sitala Bio LTD",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":21,"phases":243,"briefSummary":245,"conditions":246,"keywords":247,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100638142","early-phase-1-safety-and-efficacy-study-of-novel-gene-therapy-agx-08-for-geographic-atrophy-100638142","NCT07602127","Safety and Efficacy Study of Novel Gene Therapy AGX-08 for Geographic Atrophy","Prospective, Dose-Escalating, Investigator Initiated Trial to Evaluate the Safety and Efficacy of AGX-08 in Geographic Atrophy","Inclusion Criteria:\n\n1. Clinically confirmed diagnosis of geographic atrophy (GA) secondary to age-related macular degeneration (AMD);\n2. Age ≥ 50 years, regardless of sex;\n3. Best-corrected visual acuity (BCVA) in the study eye measured using the ETDRS chart at a starting distance of 4 meters must be ≤77 letters (Snellen equivalent ≤20\u002F63), with vision no worse than light perception; the fellow eye must not have better visual acuity than the study eye;\n4. GA lesion size between 2.5 and 17.5 mm² with clearly defined borders. For multifocal GA, at least one lesion must be ≥1.25 mm² (0.5 disc area) to ensure measurable efficacy assessment;\n5. Presence of choroidal neovascularization (CNV) in the fellow eye is allowed;\n6. Women of childbearing potential must have a negative pregnancy test (blood or urine);\n7. Women of childbearing potential and male participants must agree to use effective contraception during the study and for 3 months after completion, with no plans for reproduction;\n8. Willing and able to provide written informed consent and comply fully with the study protocol.\n\nExclusion Criteria:\n\n1. GA caused by conditions other than AMD (e.g., Stargardt disease, cone-rod dystrophy, or other inherited macular dystrophies);\n2. Aphakia in the study eye, or cataract surgery\u002FYAG capsulotomy within 3 months prior to screening;\n3. Refractive status or axial length outside the following range: spherical equivalent between -6.00D and +5.00D, and axial length between 21 mm and 26 mm;\n4. Two baseline BCVA measurements (ETDRS) taken at least 14 days apart during screening differ by \\>30%;\n5. Current or prior evidence of exudative (wet) AMD in the study eye, including retinal pigment epithelium tear, retinal vascular occlusions, history of corneal transplantation, or any neovascularization confirmed by fluorescein angiography;\n6. Active ocular diseases in the study eye, including inflammation, other macular diseases, glaucoma, ocular hypertension, or acute\u002Fchronic ocular infections;\n7. Major ocular surgery within 3 months prior to screening;\n8. History of retinal detachment or other fundus diseases unsuitable for study participation;\n9. Prior macular laser photocoagulation with irreversible retinal damage;\n10. Pregnant or lactating women, or participants unwilling to use effective contraception for 12 months before and after study intervention;\n11. Narrow anterior chamber angle or other contraindications to pupil dilation;\n12. Any ocular condition that may interfere with visual acuity assessment, OCT, or other ophthalmic evaluations;\n13. History of hypersensitivity to contrast agents, study drugs, or excipients;\n14. Allergy to corticosteroids, intolerance to protocol-required corticosteroid therapy, or contraindicated active infections;\n15. Severe systemic diseases, psychiatric disorders, uncontrolled chronic conditions, or other medical conditions that may increase study risk (e.g., malignancy, metabolic or autoimmune diseases);\n16. History of malignancy within 5 years (except cured basal cell carcinoma of the skin or cervical carcinoma in situ);\n17. Receiving or likely to receive immunosuppressive therapy outside this study;\n18. Participation in another investigational drug study within 3 months prior to screening;\n19. Prior gene therapy other than this study;\n20. Any condition that may compromise scientific evaluation of the study;\n21. Any contraindication to intravitreal (IVT) injection;\n22. Any other condition deemed unsuitable by the investigator.",{"count":5,"type":20},[244],"EARLY_PHASE1","This is AGX-08's safety, tolerability, and efficacy in Geographic Atrophy first-in-human study. This trial is meant to evaluate the safety and efficacy of AGX-08 in Geographic Atrophy patients. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.",[27],[248,249,250],"GA","AMD","dry AMD","2026-05-20",{"date":253,"type":35},"2026-05-22",{"date":63,"type":20},{"date":256,"type":20},"2029-12-30",{"name":258,"class":42},"Zhongmou Therapeutics",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":21,"phases":269,"briefSummary":271,"conditions":272,"keywords":273,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":190},"100636797","pterygopalatine-ganglion-stimulation-for-the-treatment-of-geographic-atrophy-100636797","NCT07570355","Pterygopalatine Ganglion Stimulation for the Treatment of Geographic Atrophy","Feasibility and Safety Evaluation of Pterygopalatine Ganglion Stimulation in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Controlled Pilot Study","Inclusion Criteria:\n\n* Best-corrected visual acuity (BCVA), as measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, ranging from 25 to 80 letters (Snellen equivalent, 20\u002F320 to 20\u002F25).\n* A confirmed diagnosis of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), with no involvement of the foveal center. Fundus autofluorescence (FAF) imaging must demonstrate a total GA area of 2.5 to 17.5 mm² located within a 30° field centered on the fovea, with the presence of any pattern of increased autofluorescence at the junctional zone of GA. In cases of multifocal GA, at least one lesion must be ≥1.25 mm² in size.\n\n  * If both eyes meet the eligibility criteria, the eye with the worse BCVA will be selected as the study eye. If BCVA is equal in both eyes, the right eye will be designated as the study eye.\n\nExclusion Criteria:\n\n* History or evidence of submacular surgery or other treatments for AMD in the study eye, with the exception of oral vitamin and mineral supplementation.\n* History of intraocular surgery within 3 months prior to screening, or the presence of ocular conditions requiring surgical intervention during the study period.\n* Receipt of any periocular or intravitreal injection therapy in the study eye within 3 months prior to screening.\n* History or evidence of choroidal neovascularization in either eye, or the presence of any other retinal disease that may confound the assessment of macular structure or function (e.g., diabetic retinopathy or pathologic myopia).\n* Presence of severe systemic disease or any other condition deemed unsuitable for study participation.\n* Inability to comply with scheduled visits or complete study procedures due to cognitive impairment or other factors, as judged by the investigator.","80 Years",{"count":268,"type":20},62,[270],"NA","The goal of this clinical trial is to evaluate the feasibility and safety of pterygopalatine ganglion (PPG) stimulation in adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).\n\nThe main questions it aims to answer are:\n\nIs PPG stimulation feasible to implement, as reflected by participant adherence to the intervention and completion of follow-up assessments? Is PPG stimulation safe, as assessed by the incidence of adverse events and clinical ophthalmic examinations? What are the preliminary effects of PPG stimulation on choroidal perfusion, retinal sensitivity, visual acuity, and the progression of GA lesion area?\n\nResearchers will compare active PPG stimulation with sham stimulation (a procedure that mimics the intervention without delivering real stimulation) to assess feasibility and safety, while exploring potential therapeutic effects.\n\nParticipants will:\n\nReceive active or sham PPG stimulation according to randomization over a 12-month study period Attend scheduled clinic visits for safety monitoring and multimodal ophthalmic assessments Undergo examinations including optical coherence tomography (OCT), fundus autofluorescence imaging, microperimetry, and visual acuity testing",[27],[27,274,275,276,277],"Pterygopalatine Ganglion","Sphenopalatine Ganglion","Clinical Trial","Age-related Macular Degeneration","2026-04-29",{"date":280,"type":35},"2026-05-06",{"date":282,"type":20},"2026-06-01",{"date":284,"type":20},"2028-07-31",{"name":286,"class":287},"Shanghai Institute of Acupuncture, Moxibustion and Meridian","OTHER",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":295,"sex":16,"minAge":296,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":299,"conditions":300,"keywords":304,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":190},"100198971","high-resolution-retinal-imaging-100198971","NCT01866371","High Resolution Retinal Imaging","AOSLO","Inclusion Criteria:\n\n* Males or females age 7 years or older.\n* Parental\u002Fguardian permission (informed consent) and if appropriate, child assent. Child subjects age 7-17 must give assent.\n* Reasonable compliance with an imaging protocol as determined by the study personnel.\n\nExclusion Criteria:\n\n* Individuals that are at risk to acute glaucoma.\n* Individuals that are photophobic and experience adverse psychological reactions to flashes of light.\n* Ocular opacities, high refractive error, and high frequency of nystagmus as determined by the study team.",true,"7 Years",{"count":298,"type":20},600,"Studying the morphology and function of the normal and diseased retina in vivo is needed for advancing the detection, diagnosis, and treatment of retinal disease. This protocol uses an adaptive optics scanning laser ophthalmoscope (AOSLO) to image the normal and diseased retina with individual cellular resolution non-invasively. The primary objective of this study is to obtain and analyze high-resolution images of the retina, in particular by imaging the cone photoreceptor mosaic, the retinal vasculature and other retinal layers. The study design will involve case-control studies, where cases are followed over time. Subjects age 7 and older may be invited to participate. The main research procedure involves retinal imaging with the AOSLO. The primary endpoint is the observation of differences in retinal images between subjects with and without retinal diseases. These changes will be quantified by examining the cell density, size, spacing and regularity of the cone photoreceptor mosaic, as well as examining the differences between other retinal layers.",[301,302,277,303,27],"Stargardts","Retinitis Pigmentosa","Choroideremia",[111,305,306],"imaging","retinal degeneration","2026-04-28",{"date":309,"type":35},"2026-05-05",{"date":311,"type":4},"2013-05",{"date":313,"type":20},"2031-12",{"name":315,"class":287},"University of Pennsylvania",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":325,"conditions":326,"keywords":327,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":190},"100635724","central-microperimetry-and-radial-oct-evaluation-in-geographic-atrophy-core-ga-a-prospective-pilot-study-100635724","NCT07556406","Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study","CORE-GA","Inclusion Criteria:\n\n* Subjects must be 55+ years of age Subjects in the \"Intermediate AMD Observation Arm\" must have intermediate age-related macular degeneration in one eye\n\nSubjects in the \"GA Observation Arm\", \"GA Continuing Treatment Arm\", and \"GA Treatment Arm\" must have non-central GA (defined as GA has not involved the center point of the fovea) and at least 1% GA in the central 1 mm zone.\n\nExclusion Criteria:\n\n* Subjects with central involvement of GA. Central involvement is defined as geographic atrophy involving the foveal center point.\n\nSubjects with a baseline size of GA \\> 17.5mm2 (7.0 Macular Photocoagulation Study Disc Areas).\n\nSubjects who are: pregnant women, adults who cannot consent for themselves, and those who use alcohol in excess. Excess alcohol use is defined by binge drinking (pattern of drinking that brings blood alcohol concentration levels to 0.08 g\u002FdL) on 5 or more days in the past month.\n\nEvidence of retinal atrophy due to causes other than atrophic AMD. Subjects who have had anti-VEGF injections or active choroidal neovascularization in the study eye during the last 12 months Current evidence or history of ocular disorders in the study eye that in the opinion of the investigator confounds study outcome measures, including (but not limited to):\n\n1. Non-proliferative diabetic retinopathy involving 10 or more hemorrhages or microaneurysms, or active proliferative diabetic retinopathy\n2. Branch or central retinal vein or artery occlusion\n3. Macular hole\n4. Pathologic myopia\n5. Uveitis\n6. Pseudovitelliform maculopathy\n7. Intraoperative surgery within the last 90 days prior to study eye enrollment",{"count":324,"type":20},80,"This study is being conducted to assess two imaging methods-central microperimetry and radial OCT (Optical Coherence Tomography)-in patients with Geographic Atrophy (GA) or those who are at risk of developing this condition. The study team is trying to determine whether these methods can provide more accurate measurements of GA progression toward the foveal center, the central part of the retina responsible for your sharpest, most detailed vision.",[28,27],[328,329],"age-related macular degeneration","geographic atrophy","2026-04-22",{"date":278,"type":35},{"date":333,"type":35},"2025-06-11",{"date":335,"type":20},"2027-06-11",{"name":337,"class":287},"University of California, San Francisco",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":21,"phases":348,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":43},"100558925","phase-2-a-phase-iib-randomized-multicenter-trial-of-subretinal-cpcb-rpe1-in-advanced-dry-amd-geographic-atrophy-100558925","NCT06557460","A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)","A Phase IIb, Randomized, Assessor-Masked, Multicenter Clinical Trial to Assess the Safety and Efficacy of Subretinal Implantation of the CPCB-RPE1 Implant in Subjects With Advanced, Dry Age-Related Macular Degeneration (Geographic Atrophy) - PATCH AMD","PATCH-AMD","Eligible participants include:\n\n1. Age 55 to 90 years of age (inclusive), presenting with geographic atrophy involving the fovea in advanced, age-related, dry AMD.\n2. Clinical findings consistent with advanced dry AMD with evidence of one or more areas of ≥4.0mm2 but not exceeding 15.0 mm2 of geographic atrophy involving the fovea.\n3. Geographic atrophy defined as attenuation or loss of RPE as observed by biomicroscopy, OCT, or FAF.\n4. The best-corrected visual acuity (BCVA) of the eye to receive the implant will be ≥20\u002F200 (35 EDTRS letters) to 20\u002F63 (60 EDTRS letters) inclusive. The BCVA of the eye that is NOT to receive the implant will be better or equal to the eye that will receive the implant.\n5. Medically suitable to undergo pars plana vitrectomy and the surgical implant procedure, including being able to position post-operatively and use post-operative medications as required.\n6. Medically suitable for general anesthesia or monitored intravenous sedation, if needed.\n7. Pseudophakic in the study eye, to remove the risk of cataract formation following vitrectomy.\n8. Participants also must be willing and able to provide written, signed informed consent for this study.\n9. Participants able to complete the baseline microperimetry retinal sensitivity testing.\n10. On baseline microperimetry, participants must have ≥5 spots in the perilesional region with a retinal sensitivity between 3 and 17 Db.","90 Years",{"count":5,"type":20},[24],"This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea.\n\nUp to 6 surgical implantation sites will deliver the CPCB-RPE1 in this Phase IIb clinical trial. Additional study sites may serve as referral or follow-up sites. Twenty-four (24) subjects will participate in the trial and will be randomized 3:1 to one of 2 groups:\n\n* The treatment group receiving the CPCB-RPE1 implant (up to 18 subjects).\n* The control group receiving a simulated \"sham\" implantation procedure (up to 6 subjects)",[351,27],"Dry Age-related Macular Degeneration","2026-03-22",{"date":354,"type":35},"2026-03-25",{"date":356,"type":35},"2025-08-01",{"date":358,"type":20},"2040-12",{"name":360,"class":42},"Regenerative Patch Technologies, LLC",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":295,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":21,"phases":370,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":4},"100626242","validation-of-virtual-reality-tests-for-the-assessment-of-patients-with-age-related-macular-degeneration-as-clinical-endpoints-100626242","NCT07433088","Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints","Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration","VIRETTA","Inclusion Criteria:\n\n* Age ≥ 50 years\n* Sufficient knowledge of the French language\n* Ability to give personal, express, free, and informed consent\n* Ability to comply with the requirements of the protocol\n* Person covered by Social Security\n* Clarity of the ocular environment, adequate pupil dilation to allow the collection of good quality images, as determined by the investigator\n\nAdditional inclusion criteria for group 1, healthy subjects:\n\n* No detectable visual pathologies\n* Best monocular visual acuity ≥ 8\u002F10\n\nAdditional inclusion criteria for group 2, subjects with LMA, early AMD, or intermediate AMD without atrophy:\n\n* Diagnosis of AMD, early AMD, or intermediate AMD\n* Absence of geographic atrophy\n* Presence of drusen (diameter \\> 63 µm) with or without pigmentary changes\n\nAdditional inclusion criteria for group 3, subjects with dry AMD with perifoveal atrophy:\n\n* Diagnosis of atrophic AMD\n* Presence of drusen (diameter \\> 125 µm)\n* Location of geographic atrophy as determined by the investigator: extrafoveal, juxtafoveal\n* Preservation of central vision confirmed by the investigator based on a comprehensive and integrated interpretation of SD-OCT, FAF, retinography, and best corrected visual acuity examinations.\n\nAdditional inclusion criteria for group 4, Subject with dry AMD with foveal atrophy:\n\n* Diagnosis of atrophic AMD\n* Presence of drusen (diameter \\> 125 µm)\n* Investigator's localization of geographic atrophy: retrofoveal\n* Central vision impairment confirmed by the investigator based on a comprehensive and integrated interpretation of SD-OCT, FAF, retinography, and best corrected visual acuity examinations.\n\nExclusion Criteria:\n\n* Pregnant women, women in labor, or breastfeeding women\n* Subjects undergoing drug treatments that may cause motor, visual, vestibular, or cognitive disorders (PSA, neuroleptics, etc.) or that could interfere with the study examinations\n* Any concomitant intraocular condition in the eye being studied (e.g., glaucoma or cataract)\n* Any retinal pathology that could cause retinal atrophy other than AMD (eliminate dystrophy, chronic CRSC, pachyatrophy, resorption of vitelliform material with atrophy, high myopia, etc.)\n* Known systemic disease that, in the investigator's opinion, would prevent active participation in the study\n* Participation in any other therapeutic study evaluating a drug.\n* Subjects with cognitive impairment, illiterate subjects, and subjects who do not speak the national language.\n* Persons subject to enhanced protection or legal safeguards (guardianship, trusteeship).",{"count":133,"type":20},[270],"Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries and affects tens of millions of people worldwide, with a rapidly increasing prevalence. It causes irreversible central vision loss and significant difficulties in daily activities, impairing patients' quality of life and independence. Conventional clinical assessments, which focus on visual acuity and retinal imaging, do not fully reflect the functional impact of the disease.\n\nVirtual reality (VR) makes it possible to create immersive, controlled environments to accurately measure functional vision and simulate real-life situations. The study proposes to develop a standardized and reproducible functional test in virtual reality that can complement conventional examinations and support clinical and industrial research.",[373,27,374],"Dry AMD","Healhty","2026-02-18",{"date":377,"type":35},"2026-02-25",{"date":379,"type":20},"2026-04",{"date":381,"type":20},"2027-04",{"name":383,"class":42},"Streetlab",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":295,"sex":16,"minAge":168,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":394,"conditions":395,"keywords":410,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":4},"100615866","wide-field-octa-in-ocular-diseases-100615866","NCT07298174","Wide Field OCTA in Ocular Diseases","Wide Field OCTA in Ocular Diseases: a Prospective Observational Study of the Clinical Impact of Wide Field OCTA in Ocular Disease.","WOOD-2025","Inclusion Criteria:\n\n* Age \\> 18 years\n* Both genders\n* Confirmed diagnosis of one of the above diseases\n* Age-related macular degeneration\n* Diabetic retinopathy\n* Myopia\n* Pachychoroid spectrum disease\n* Inherited retinal dystrophy\n* Uveitis\n* Dry eye\n* Visual acuity of at least 1\u002F20\n* Signed informed consent for the participation to the trial.\n\nExclusion Criteria:\n\n* Media opacities\n* Any other eye or systemic condition that may irreversibly impair the results of the study\n* Surgery in the eye in the study, including cataract extraction, in the three months prior to recruitment",{"count":393,"type":20},200,"The main retinal diseases, whether or not associated with specific mutations genetic, cause progressive degeneration of vascular retinal structures and not vascular, resulting in decreased visual function. Often, such diseases affect the noblest part of the retina, called macula. Many retinal diseases can be complicated by choroidal neovascularization which causes frequent bleeding and fluid leakage that accumulates in the subretinal and intraretinal spaces. Although the investigators know many details of each disease affecting the retina, very often the correct diagnostic framework can be complicated, given the presence of morphological elements common to the different pathologies. Similarly, predicting the effect of treatment and the patient's outcome is a constant challenge for the ophthalmologists. Most of the current research has been focused on the assessment of vascular alterations localized in the macula. However, growing evidence highlight the importance of peripheral vascular changes on the outcome of retinal diseases. These changes can be detected only be wide field OCT devices.\n\nOn the other hand, ocular inflammation and hyperemia represent major assessments in anterior segment disorders, such as dry eye disease. The current grading systems of ocular inflammation, redness and hyperemia are characterized by several limitations, thus making these evaluations still mainly confined to the subjective assessment performed by the ophthalmologist. However, the new generation OCT devices may include also an anterior segment module which can reconstruct anterior segment vessels, non-invasively, using the same technology described for retinal diseases.\n\nThe main goal of the study is to evaluate the diagnostic contribution of a new generation wide field OCTA device in ocular diseases, which has recently received CE marking. In particular, the investigators will evaluate this new generation device both in retinal and anterior segments diseases, testing for common points and differences with the standard of care non-invasive diagnostic devices. Secondary outcomes include the assessment of the correlation between the patient's visual function (visual acuity) and morphological changes (standard of care imaging assessment) highlighted by the wide field OCT device, with particular attention to microstructural differences between major ocular diseases and the possible development of non-invasive biomarkers, useful for the diagnosis and follow-up of such pathologies.",[396,397,398,399,400,174,401,402,27,403,404,405,406,407,408,409],"Age - Related Macular Degeneration (AMD)","Diabetic Macular Edema","Diabetic Retinopathy","Myopia","Inherited Retinal Disease","Retinitis Pigmentosa (RP)","Best Disease","Macular Neovascularisation","Ocular Surface Disease","Central Serous Choroidopathy","Pachychoroid Disease","Uveitis","Vitreoretinal Disease","Retinal Vein Occlusion",[411,412,413,414,415,416],"wide-field octa","multimodal retinal imaging","quantitative imaging","retinal disease","macular disease","ocular surface disease","2025-12-22",{"date":419,"type":35},"2025-12-30",{"date":421,"type":20},"2026-01",{"date":423,"type":20},"2028-05",{"name":425,"class":287},"IRCCS San Raffaele",{"id":427,"slug":428,"hasResults":11,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":21,"phases":435,"briefSummary":436,"conditions":437,"keywords":442,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":190},"100606371","phase-2-sglt2-inhibitors-in-geographic-atrophy-100606371","NCT07174687","SGLT2 Inhibitors in Geographic Atrophy","Efficacy of Dapagliflozin in the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration","Inclusion Criteria:\n\n1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol\n2. Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures\n3. Participant is male or, if female, participant is surgically sterilized or amenorrheic for at least one year\n4. ≥50 years old\n5. Evidence of dry advanced AMD with the presence of non-foveal Geographic Atrophy (GA)\n\n   1. The geographic atrophy must not involve the center point of the fovea.\n   2. Total area of geographic atrophy must be between 2.5 mm2 and 17.5 mm2 (1 - 4 disc areas, respectively).\n   3. If the geographic atrophy consists of multiple lesions, at least one lesion must have an area of ≥1.25 mm² (equivalent to 0.5 disc areas).\n6. BCVA between 20\u002F25 and 20\u002F320\n7. Must be treatment-naïve for AMD, except for oral supplements\n\nExclusion Criteria:\n\n1. Prior investigational drug use within 60 days\n2. Use of other SGLT2 inhibitors\n3. History of symptomatic hypotension or symptomatic hypotension (symptoms of hypotension + SBP \\\u003C 90mmHg) at baseline\n4. Type I and Type II Diabetes Mellitus\n5. End stage renal disease or estimated glomerular filtration rate less than 25 mL\u002Fmin\u002F1.73 m2 per MDRD calculation\n6. History of heart failure\n7. History of a serious hypersensitivity reaction to dapagliflozin or any of the excipients in FARXIGA\n8. Other concomitant disease or condition that investigator deems unsuitable for the study, including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the study instructions or follow-up procedures\n9. Any prior treatment for AMD (dry or wet) or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins or mineral\n10. Any intraocular surgery or thermal laser within 3 months of date of randomization\n11. Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks\n12. Any prior thermal laser in the macular region, regardless of indication (self-report)\n13. Any evidence of choroidal neovascularization in study eye\n14. Enrollment in another interventional trial during the trial period",{"count":434,"type":20},70,[24],"AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration. The primary objectives of the study are to assess the safety, tolerability, and evidence of activity of SGLT2 inhibitors in subjects with Geographic Atrophy associated with AMD.",[438,439,440,27,441],"Retinal Degeneration","Retinal Diseases","Eye Diseases","Pathological Conditions, Anatomical",[443,277,249,444,445],"Geographic Atrophy (GA)","SGLT2","Dapagliflozin","2025-12-16",{"date":448,"type":35},"2025-12-18",{"date":450,"type":35},"2025-12-02",{"date":452,"type":20},"2028-06",{"name":454,"class":287},"Washington University School of Medicine",{"id":456,"slug":457,"hasResults":11,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":21,"phases":464,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":477},"100522810","phase-1-study-of-voy-101-in-patients-with-advanced-non-neovascular-age-related-macular-degeneration-100522810","NCT06087458","Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration","Phase 1\u002F2a Dose Escalation Study of VOY-101 in Patients With Advanced Non- Neovascular Age-Related Macular Degeneration","JOURNEY","Inclusion Criteria:\n\n* Are ≥60 years of age at the time of consent.\n* Are willing and able to understand and provide written informed consent.\n* Are willing and able to return for scheduled treatment and follow-up examinations.\n* Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.\n* Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.\n* Absence of signs of non-exudative MNV.\n* Additional Ocular Inclusion Criteria for both eyes.\n* Meet certain genotype criteria for risk of AMD.\n\nExclusion Criteria:\n\n* Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.\n* Additional Systemic, Ocular, and Genetic Exclusion Criteria.",{"count":133,"type":20},[23,24],"The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.",[28,27,467],"Non-neovascular AMD","2025-10-13",{"date":470,"type":35},"2025-10-15",{"date":472,"type":35},"2023-06-21",{"date":474,"type":20},"2028-03",{"name":476,"class":42},"Perceive Biotherapeutics, Inc.",11,{"id":479,"slug":480,"hasResults":11,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":21,"phases":486,"briefSummary":487,"conditions":488,"keywords":489,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":4},"100595245","phase-1-a-phase-12-study-of-the-safety-and-efficacy-of-brx011-oral-administration-once-daily-in-subjects-with-geographic-atrophy-secondary-to-age-related-macular-degeneration-100595245","NCT07029945","A Phase 1\u002F2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration","Inclusion Criteria:\n\n1. Age ≥55 years\n2. Visual acuity in the study eye at Screening\u002FBaseline\n\n   1. BCVA ≥35 letters using ETDRS charts (≥20\u002F200 Snellen equivalent)\n   2. LLD \\>5 letters\n3. Clinical diagnosis of GA secondary to AMD. CNV in the fellow eye is permitted.\n\n(5) Clarity of ocular media, adequate pupillary dilation, and fixation to permit the evaluation of the eye, as determined by the investigator\n\n(6) Female subjects must be of non-child-bearing potential (WONCBP), defined as:\n\n(a) A woman who had surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) (b) A woman ≥ 60 years of age (c) A woman ≥ 55 and \\\u003C 60 years of age who fulfills at least one of the following: (i) A cessation of menses for at least 12 months and a folliclestimulating hormone (FSH) test confirming non-childbearing potential (refer to laboratory reference ranges for confirmatory levels) (ii) A cessation of menses for at least 24 months without FSH levels confirmed.\n\n(7) Willing and able to give informed consent and to comply with the study procedures and assessments\n\nExclusion Criteria:\n\n1. GA secondary to a condition other than AMD such as Stargardt disease, cone rod dystrophy or toxic maculopathies like plaquenil maculopathy in either eye\n2. Any history documented or active CNV\n3. Any ocular condition other than GA secondary to AMD that may require surgery or medical intervention during the study period\n\n(5) History of vitrectomy surgery, submacular surgery, other surgical intervention for AMD, corneal transplant, glaucoma filtration surgery, or cataract surgery within 3 months prior to Screening\u002FBaseline\n\n(6) History of intravitreal injection of anti-vascular endothelial growth factor (VEGF) therapies in the study eye at any time, history of intravitreal injection of any agent (e.g., triamcinolone) in the study eye within the last 3 months prior to study enrollment. A single intraoperative administration of a corticosteroid during cataract surgery at least 3 months prior to Screening is permitted\n\n(7) History of laser therapy in the macular region in the study eye, prior treatment with photobiomodulation, external-beam radiation therapy or transpupillary thermotherapy in study eye\n\n(8) Previous cell-based intraocular treatment in the study eye or previous expression vector-mediated intraocular treatments in either eye (i.e., gene therapy), any previous treatment with any deuterated molecules for eye diseases (e.g., deuterated vitamin A)\n\n(9) History of idiopathic or autoimmune-associated uveitis, ocular or intraocular conditions, and infectious or inflammatory ocular disease. Active uveitis and infectious conjunctivitis, keratitis, scleritis or endophthalmitis\n\n(11) Active malignancy within the previous 12 months except for appropriately treated carcinoma in situ of cervix, resolved non-melanoma skin carcinoma, and prostate cancer with a Gleason score of less than or equal to (≤) 6, and a stable prostate-specific antigen for greater than or equal to (≥) 12 months\n\n(13) Intake of omega-3 supplements (e.g., fish oil, cod liver oil, krill oil, edible algae oil, flax oil) or prescription omega-3 drugs (e.g., Lovaza® , Vascepa® , Epanova® ) in the past 4 weeks prior to Screening and throughout the duration of the study; intake of supplements containing Lutein, zeaxanthin and or mesozeaxanthin (e.g., Ocuvite® , PreserVision® , SYSTANE ICAPS ® or other AREDS supplements) in the past 4 weeks prior to Screening and throughout the duration of the study\n\n(14) Participation in an interventional clinical study within the past 30 days of Screening, or interventional GA studies within the past 5 months prior to Screening\n\n(15) Treatment with SYFOVRE ®or IZERVAY ®within 3 months prior to Screening",{"count":485,"type":20},152,[23,24],"This study aims to evaluate the safety and efficacy of BRX011, an oral medication, taken once daily by participants with geographic atrophy secondary to age-related macular degeneration. The study is conducted in phases 1 and 2, focusing on assessing both safety (tolerability) and effectiveness (efficacy) of the treatment.\n\nParticipants: Adults with geographic atrophy due to age-related macular degeneration.\n\nTreatment: BRX011 or Placebo is taken once daily as per the protocol.\n\nDuration: The study involves multiple visits over 96 weeks to monitor participants' health and response to treatment.\n\nSafety Monitoring: Regular checks for adverse events and health status to ensure participant well-being. Checks will include examination of vital signs, clinical labs, ocular exams, and ocular imaging.\n\nPrimary Outcome Measure: Efficacy of BRX011 in the annual rate of change in the square root of GA area, as specified in the protocol.",[27],[27,249,28,490,491,248],"Oral","Oral Therapy","2025-06-23",{"date":494,"type":35},"2025-06-26",{"date":496,"type":20},"2025-07-07",{"date":498,"type":20},"2027-02-11",{"name":500,"class":42},"Biojiva LLC",{"id":502,"slug":503,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":509,"enrollmentInfo":510,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":522},"100543114","personalized-monitoring-of-non-foveal-non-vision-compromising-atrophic-age-related-macular-degeneration-with-artificial-intelligence-and-identification-of-disease-progression-100543114","NCT06351657","Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression","Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression in a Prospective, Multinational, Multicenter Observational Study","APENNINES","Inclusion Criteria:\n\n* Age: 55-99 years old\n* Complete RPE and outer retinal atrophy (cRORA). This is (1) a region of hypertransmission of at least 250 µm in diameter, (2) a zone of attenuation or disruption of the RPE of at least 250 µm in diameter, (3) evidence of overlying photoreceptor degeneration, and (4) absence of scrolled RPE or other signs of an RPE tear.\n* If both eyes are eligible, both eyes will be included in the cohort study.\n* Clear optical media and adequate pupillary dilation for imaging and functional testin\n\nExclusion Criteria:\n\n* Any surgical treatment of the eye within 3 months prior to baseline in the study eye\n* History of anti-VEGF treatment in the study eye before baseline\n* History of pseudophakic cystoid macular edema (Irvine Gass Syndrome) in the study eye\n* History of uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) ≥ 25 mmHg despite treatment with IOP lowering medication), or C\u002FD Ratio \\> 0.9\n* Any concurrent intraocular condition in the study eye (e.g. advanced cataract or moderate\u002Fsevere diabetic retinopathy) that, in the opinion of the investigator, will most likely require medical or surgical intervention during the study period to prevent or treat visual loss that might result from that condition\n* Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could cause an unwanted effect on treatment efficacy, compliance or require intraocular surgery (except for cataract surgery and YAG capsulotomy) during the study period\n* Presence of corneal decompensation, haze or scarring with an impact on BCVA\n* Refractive error larger than 6 diopters. In case of pseudophakia or refractive surgery: History of refractive error larger than 6 diopters.\n* Intake of drugs known to cause retinal toxicity (e.g. hydroxychloroquine or tamoxifen)\n* Presence of active macular neovascularization at baseline.","99 Years",{"count":393,"type":20},"The goal of this prospective, multinational, multicenter observational study is to assess and predict progression in non-foveal, non-vision compromising atrophic AMD on an individual-based level over two years. The main objectives of this study are:\n\n* Assess the individual progression rate of a patient in non-foveal, non-vision compromising atrophic AMD and assess personalized risk of progression based on imaging.\n* Identify and quantify focal and global alterations in the retina in regard to disease progression.\n* Evaluate the monitoring of AMD progression using approved AI algorithms.\n\nAll patients will be followed for 24 months with 6 month intervals to assess clinical changes. Monitoring of disease progression will be performed using the following routine in-vivo imaging procedures:\n\n* Scanning Laser Fundus Photography\n* Color Fundus Photography (CFP)\n* Optical Coherence Tomography (OCT)\n* Optical Coherence Tomography Angiography (OCTA)\n\nPatients will be asked for their medical history. Standard ophthalmic examination, as well as a questionnaire on visual function will be carried out.\n\nNo intervention will be performed during the study since no treatment is yet available within Europe. As soon as treatment is approved in the EU, patients in this cohort might receive treatment according to availability in their respective country and standard of care. If treatment will be performed, it will be as standard of care outside the study according to each country's standard of care and by EMA label.",[28,27],"2025-05-12",{"date":515,"type":35},"2025-05-15",{"date":517,"type":35},"2025-04-11",{"date":519,"type":20},"2027-07",{"name":521,"class":287},"Medical University of Vienna",7,{"id":524,"slug":525,"hasResults":11,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":295,"sex":16,"minAge":168,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":532,"conditions":533,"keywords":534,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":190},"100577990","a-prospective-observational-study-to-assess-the-reliability-and-validity-of-the-mlsdt-100577990","NCT06805474","A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT","A Prospective Observational Study to Assess the Reliability and Validity of the Multi-Luminance Shape Discrimination Test (MLSDT) With 9 Objects","Inclusion Criteria:\n\n* Males and females, age ≥ 18 years\n* Able to comprehend and give informed consent.\n* Able to comply with testing and all protocol tests.\n* Eligible for 1 of 3 cohorts listed below:\n\nCohort 1: Normal-Sighted Participants with clinically normal ocular findings and BCVA range 20\u002F16 to \\\u003C20\u002F40 in each eye (ETDRS letter score 71 - 90) Cohort 2: Moderately-Sight Impaired Participants with a BCVA range of 20\u002F40 to \\\u003C20\u002F200 (ETDRS letter score of 36 - 70) and a clinical diagnosis of STGD\u002FGA Cohort 3: Severely-Sight Impaired Participants with a BCVA range of 20\u002F200 to 20\u002F800 (ETDRS letter score of 5 - 35) and a clinical diagnosis of advanced STGD\u002FGA\n\n* Clinical diagnosis of STGD for cohorts 2 and 3\n* Clinical diagnosis for GA (due to AMD) for cohorts 2 and 3\n* Participants who have had anti-VEGF therapy 2 weeks prior to enrollment have to demonstrate 3 months of vision stability and be fluid free on OCT.\n\nExclusion Criteria:\n\n* Concurrent participation in any interventional clinical trial or receipt of an investigational drug within the previous 6 months\n\n  * Presence of any condition other than STGD or GA from AMD on slit lamp exam or dilated ophthalmoscopy that impairs visual acuity or visual fields e.g., corneal opacity, visually significant cataract or visual field loss in glaucoma\n  * No intra-vitreal injection with anti-VEGF two weeks prior to the study\n  * Presence of neurological condition that impairs visual acuity\n  * Individuals who refuse or are incapable of performing the MLSDT of BCVA tests\n  * Individuals with retinal prosthesis (such as ARGUS-II)",{"count":531,"type":20},30,"The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when tested without a wearable low-vision magnifying aid (eGlasses) and then with eGlasses. These results will be compared to ETDRS testing results for the same participants without eGlasses and then with eGlasses. Two cohorts will consist of participants who have vision loss due to STGD or geographic atrophy (GA) due to age-related macular degenerations (AMD). Normally sighted participants will provide a control group.",[56,27,174],[535,536,537,538],"Multi-Luminance Shape Discrimination Test","low-vision magnifying aid (eGlasses)","best-corrected visual acuity (BCVA)","Early Treatment Diabetic Retinopathy Study ETDRS","2025-03-18",{"date":541,"type":35},"2025-03-24",{"date":543,"type":35},"2025-01-28",{"date":545,"type":20},"2025-05-27",{"name":547,"class":42},"Nanoscope Therapeutics Inc.",{"id":549,"slug":550,"hasResults":11,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":554,"eligibilityCriteria":555,"healthyVolunteers":11,"sex":16,"minAge":556,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":21,"phases":559,"briefSummary":560,"conditions":561,"keywords":562,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":574},"100472964","multicenter-clinical-study-of-the-sing-imt-in-patients-with-late-stage-amd-100472964","NCT05438732","Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD","A Prospective, Multicenter Clinical Study of the Implantable Miniature Telescope, Model SING in Patients with Central Vision Impairment Associated with End-stage Age-related Macular Degeneration (AMD)","CONCERTO","Inclusion Criteria:\n\n1. Be at least 65 years of age at the Pre-operative Visit;\n2. Have ETDRS BCDVA 0.9 to 1.6 logMAR (20\u002F160 to 20\u002F800) at the Pre-operative Visit caused by bilateral central scotomas associated with end-stage AMD;\n3. Have bilateral retinal findings of geographic atrophy or disciform scar with foveal involvement, as determined by standard of care fluorescein angiography (FA) prior to the Pre-operative Visit;\n4. Have been monitored by an eye care professional over the 6-month (or longer) period immediately prior to the Pre-operative Visit and have demonstrated no evidence of active choroidal neovascularization (CNV) prior to the Pre-operative Visit as demonstrated by the following:\n\n   1. lack of need of treatment for CNV over the past 6 months, and\n   2. lack of active exudative fluid on optical coherence tomography (OCT) over the past 6 months, and\n   3. lack of Retinal hemorrhage on exam over a 6-month period or longer\n5. Agree to participate in post-operative visual training\n\n   For the Implanted Eye:\n6. Have evidence of visually significant cataract at the Pre-operative Visit;\n7. Agree to undergo pre-operative training and assessment (1 or more sessions) with low vision specialists (optometrist or occupational therapist) in the use of an external telescope model sufficient for patient assessment and patient must achieve at least a 5-letter ETDRS BCDVA improvement (0.1 logMAR) in the final assessment\n\n   For the Non-Implanted Eye:\n8. Have adequate peripheral vision at the Pre-operative Visit to allow navigation\n\nExclusion Criteria:\n\n1. Have cognitive impairment that would interfere with the ability to understand and provide Informed Consent or prevent proper visual training\u002Frehabilitation with the device;\n2. Have any of the following conditions at the Pre-operative Visit:\n\n   1. Stargardt macular dystrophy;\n   2. Diabetic retinopathy;\n   3. Untreated retinal tears;\n   4. Retinal vascular disease;\n   5. Optic nerve disease;\n   6. History of retinal detachment;\n   7. Intraocular tumor;\n   8. Retinitis pigmentosa;\n3. History of steroid-induced rise in intraocular pressure (IOP), uncontrolled glaucoma, or IOP \\>22 mmHg at the Pre-operative Visit;\n4. Have known allergy to post-operative medications;\n5. History of eye rubbing or an ocular condition that predisposes subject to eye rubbing;\n6. Have had prior or expected ophthalmic surgery within 30 days of the Operative Visit;\n7. Have any circumstance that, based on the Investigator's judgment, poses a concern for the subject's safety;\n8. Any systemic disease or clinical evidence of any condition at the Pre-operative Visit which would make the subject in the opinion of the investigator unsuitable for the study;\n9. Concurrent participation or prior participation in any investigative drug or device study within last 30 days prior to Pre-operative Visit\n\n   For the Implanted Eye:\n10. Have central anterior chamber depth (ACD) \\\u003C3.0 mm from the posterior surface of the cornea (endothelium) to the anterior surface of the crystalline lens at the Pre-operative Visit;\n11. Have an Endothelial Cell Density (ECD) below:\n\n    1. 2,000 cells per millimeter, if 65-84 years old;\n    2. 1,800 cells per millimeter, if 85 years old or greater (based on the lowest value of the three cell counts performed by technician at investigative site at the Pre-operative Visit)\n12. Have a history of corneal stromal or endothelial dystrophies, including guttata;\n13. Have Myopia \\> 6.0 D or Hyperopia \\> 4.0 D by Manifest Refraction at the Pre-operative Visit;\n14. Have an Axial Length (AL) \\\u003C 21 mm at the Pre-operative Visit;\n15. Have a narrow angle defined as \\\u003C grade 2 on the Schaffer scale at the Pre-operative Visit;\n16. Ongoing Inflammatory ocular disease at the Pre-operative Visit;\n17. Zonular weakness\u002Finstability of crystalline lens, or pseudoexfoliation at the Pre-operative Visit;\n18. Have any condition at the Pre-operative Visit which in the judgement of the Investigator indicates that the haptics cannot be placed within the capsular bag during surgery;\n19. Have had previous intraocular or corneal surgery, including any type of surgery for refractive or therapeutic purposes;\n\n    For the Non-Implanted Eye:\n20. Have ophthalmic pathology at the Pre-operative Visit that compromises the patient's peripheral vision based on the Investigator's judgment.","65 Years",{"count":558,"type":20},125,[270],"The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).",[28,27],[563,564],"cataract","best-corrected distance visual acuity","2024-11-27",{"date":567,"type":35},"2024-12-03",{"date":569,"type":35},"2022-06-16",{"date":571,"type":20},"2025-12",{"name":573,"class":42},"VisionCare, Inc.",10,{"id":576,"slug":577,"hasResults":11,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":582,"enrollmentInfo":583,"targetDuration":4,"studyType":21,"phases":585,"briefSummary":586,"conditions":587,"keywords":589,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":603},"100546384","phase-1-safety--efficacy-of-eyecyte-rpe-in-patients-with-geographic-atrophy-secondary-to-dry-age-related-macular-degeneration-100546384","NCT06394232","Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.","A Phase 1\u002F2a Multi-Center, Dose-Escalation Study to Evaluate the Safety & Efficacy of Eyecyte-RPE™ When Administered as a Single-dose Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration","Inclusion Criteria:\n\n1. Men and women ≥ 50 years of age at Screening.\n2. Diagnosis of Geographic Atrophy secondary to d-AMD\n3. Have Best Corrected Visual Acuity (BCVA) equal to or less than 20\u002F200 Snellen (ETDRS letter score ≤ 35) in the study eye at screening.\n\n   1. Phase 1 ≤ 20\u002F200 and\n   2. Phase 2a ≥ 20\u002F64 (ETDRS letter score 60) in the study eye at Screening.\n4. Vision in the unoperated eye must be better or equal to vision in the study eye.\n5. Willing, committed, and able to return for ALL clinic visits and complete all study related procedures.\n6. Be medically suitable to undergo anesthesia, vitrectomy and subretinal injection in the opinion of the Investigator.\n7. Be medically suitable for immunosuppression therapy in accordance with the requirements of this protocol in the opinion of the Investigator.\n8. Able to read (or if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member) and understand, and willing to sign the informed consent form (ICF)\n9. Willing to provide signed Informed Consent prior to any procedures being performed at Visit 1, Screening.\n10. Negative for HIV, HbsAg, HCV, TB\n11. The GA lesion must meet the following criteria as determined by the central reading center's assessment of Fundus Autofluorescence (FAF) imaging at screening:\n\n    1. Total GA area must be ≥ 1.25 and ≤ 17.5 mm2 (0.5 and 7 disk areas \\[DA\\] respectively)\n    2. The entire GA lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any areas of peripapillary atrophy.\n    3. At least one of the lesions has to be sub-foveal.\n\nExclusion Criteria:\n\n1. Have evidence of neovascular AMD in either eye by clinical examination, fluorescein angiography or optical coherence tomography.\n2. Have GA secondary to a condition other than AMD such as Stargardt disease, cone rod dystrophy or toxic maculopathies like Chloroquine maculopathy in either eye.\n3. Have any evidence of active or inactive choroidal neovascularization (CNV) due to other causes such as ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, uveitis, punctate inner choroidopathy, or multifocal choroiditis in the study eye.\n4. Axial myopia greater than -6 diopters or axial length more than 26 mm.\n5. Have a decrease in BCVA in the study eye due to causes other than GA (e.g., pigment abnormalities, dense sub foveal hard exudates, previous vitreoretinal surgery, retinal dystrophies, non-retinal conditions, visually significant cataract, macular ischemia, etc.).\n6. Have the presence of retinal pigment epithelial tears or rips involving the macula in the study eye at screening.\n7. Have a history or evidence of vitreous hemorrhage in the study eye.\n8. Have a history or clinical evidence of severe diabetic retinopathy, diabetic macular edema, retinal vein occlusion or any other vascular disease affecting the retina in the study eye.\n9. Have had a prior pars plana vitrectomy in the study eye.\n10. Have a history of retinal detachment or treatment or surgery for retinal detachment in the study eye.\n11. Have history of a macular hole in the study eye.\n12. Have had any other ocular surgery (except cataract) within 2 months or Yttrium Aluminum Garnet (YAG) laser capsulotomy in the study eye in the past 4 weeks.\n13. Have had a prior trabeculectomy or other filtration surgery in the study eye.\n14. History of any form of glaucoma in the study eye.\n15. Patients with ocular pathology, particularly that of retina (other than AMD).\n16. Have active intraocular inflammation or a history or evidence of uveitis in either eye.\n17. Have active ocular or periocular infection in either eye, or a history of any ocular or periocular infection within the 2 weeks prior to Visit 1, Screening in either eye.\n18. Have a history of scleromalacia in either eye.\n19. Have had previous therapeutic radiation in the study eye.\n20. Have a history of corneal transplant or corneal dystrophy.\n21. Have any concurrent ocular condition in the study eye which, in the opinion of the investigator, could either increase the risk to the subject beyond what is to be expected from standard procedures of intraocular injection, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety.\n22. Have a history of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk for treatment complications.\n23. Have participated as a subject in any clinical study within 6 months prior to Day 0, Baseline.\n24. Have a known serious allergy to fluorescein sodium for injection in angiography, Povidone Iodine or any of the other medications required for anesthesia or the subretinal injection procedure.\n25. Be a female who is pregnant, breastfeeding, or of childbearing potential, unwilling to practice adequate contraception throughout the study at Screening and Baseline.\n26. Currently receiving aspirin, aspirin containing products and\u002For any other coagulation modifying drugs which cannot be discontinued 7 days prior to surgery.\n27. Have any systemic condition that would qualify the subject as being immunocompromised (e.g., severely uncontrolled diabetes, cancer).\n28. Patients with Optic Atrophy","100 Years",{"count":584,"type":20},54,[23,24],"The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD).\n\nThe main questions it aims to answer are:\n\n* Safety and tolerability of the novel stem cell formulation\n* Potential efficacy of the novel stem cell formulation\n\nParticipants will receive a single subretinal injection in their study eye and followed up for safety.\n\nThis is an India only study and the product is developed indigenously.",[588,56,28,27,440],"Retinal Disease",[176,27,590,591,592,593],"Visual Impairment","Subretinal injection","Stem cells","Retinal Pigment Epithelial Cells","2024-09-23",{"date":596,"type":35},"2024-09-24",{"date":598,"type":35},"2024-06-04",{"date":600,"type":20},"2030-12",{"name":602,"class":42},"Eyestem Research Pvt. Ltd.",3,{"id":605,"slug":606,"hasResults":11,"nctId":607,"briefTitle":608,"officialTitle":608,"acronym":609,"eligibilityCriteria":610,"healthyVolunteers":295,"sex":16,"minAge":168,"maxAge":4,"enrollmentInfo":611,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":613,"conditions":614,"keywords":615,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":190},"100419253","project-amd-comprehensive-characterisation-of-age-related-macular-degeneration-and-its-progression-100419253","NCT04739319","Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression","Project AMD","Inclusion Criteria:\n\n1. 18 years of age or older; and\n2. either AMD (defined as having at least a medium druse \\>63 um), or having eyes with normal ageing changes (including small drusen ≤63 um) or no abnormalities as control participants\n\nExclusion Criteria:\n\n1. ocular or systemic conditions other than AMD that could compromise retinal assessment or assessment of AMD and its progression; or\n2. any participant with any mental or physical impairment that prevents them from signing an informed consent form or participating in this study.",{"count":612,"type":20},2500,"Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss worldwide, and nearly two million Australians have some signs of AMD. This proposed project is a prospective, observational study that seeks to to understand the underlying aetiology of AMD, factors associated with differences between age-related macular degeneration (AMD) phenotypes or severities, or between AMD and healthy individuals. It also seeks to understand the natural history of AMD progression and the factors associated with the rate of progression. In this project, the disease phenotype, genotype and severity and rate of progression will be determined based on non-invasive clinical imaging or functional assessment of the retina, from obtaining biological samples from the participants, or from patient-reported outcomes.",[176,27,249,277],[176,27,616,617],"Drusen","Macular disease","2024-02-07",{"date":620,"type":35},"2024-02-09",{"date":622,"type":35},"2021-02-02",{"date":624,"type":20},"2040-11",{"name":626,"class":287},"Center for Eye Research Australia"]